Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 1.

Journal Article

Buisseret, L., Loirat, D., Aftimos, P. G., Punie, K., Maurer, C., Debien, V., Goncalves, A., Ghiringhelli, F., Taylor, D., Clatot, F., van den Mooter, T. F. A., Ferrero, J-M., Bonnefoi, H., Canon, J-L., Duhoux, F. P., Bazan, F., Kristanto, P., de Azambuja, E., Ignatiadis, M. and Piccart, M. (2022). Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). Ann. Oncol., 33 (7). S. S1385 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

This list was generated on Sun May 26 06:31:34 2024 CEST.